Approved labelSUPPRELIN LA prescribing information for central precocious puberty
PopulationPediatric patients covered by the approved SUPPRELIN LA indication
DoseOne 50 mg implant releasing approximately 65 mcg daily
RouteSubcutaneous implant in the inner upper arm
FrequencyReplace every 12 months
DurationAnnual replacement while treatment remains indicated
PreparationSterile 50 mg implant supplied for insertion by a trained healthcare professional; not reconstituted.